Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science/Astellas Pharma
Latest Information Update: 28 Oct 2022
At a glance
- Originator Anaeropharma Science; Astellas Pharma
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in Japan (Parenteral)
- 25 Sep 2018 Anaeropharma Science and Astellas Pharma establish a joint research agreement for development of recombinant Bifidobacterium anticancer therapeutics
- 25 Sep 2018 Early research in Cancer in Japan (Parenteral)